The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…
Alexa
Recommended Posts
- Like laundry, living with MS requires ongoing maintenance
- New initiative to support MS treatment decisions in older adults
- Age plays role in how RRMS affects brain volume over time
- A columnist’s perspective on adaptation and humor with MS
- Neurologist Kappos wins Dystel Prize for advancing MS research